9/10/2026
FDA outlines new psychedelic drug framework in NEJM
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
Topic archive
depression
3 stories
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
7/24/2026
Experience Ibogaine supports 3,000 patients in recovery
The Tijuana-based center marks a milestone in ibogaine treatment for substance use disorder.